A Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 315 participants.

Also called NCT01951235

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 315 participants (enrolled count) (from the registry)
Sponsor
Poxel SA (from the registry)
Registry
  • NCT NCT01951235
  • EudraCT 2012-004045-33
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Latvia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01951235. Randomized; quadruple masking; primary purpose treatment. Start 2013-01 (registry gives no type); primary completion 2014-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Imeglimin
Intervention (Drug)
Placebo
Lead sponsor
Poxel SA (class: industry)

Record details

Record id
cardio:ct-nct01951235
Content hash
ab10ac2fcc1cf4ff9e97f7ccac59868d2acc0be404ae0a8721f03038323045ff